Journal article

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine /- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, Masa Lasica, Andrew Grigg, Pietro R Di Ciaccio, Jonathan Wong, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K Yannakou, Nada Hamad, Gareth P Gregory, Shane A Gangatharan, Tara Cochrane, Kristen Piper, Leonid Churilov, Eliza A Hawkes

Blood | American Society of Hematology | Published : 2020


Background: Bendamustine +/- anti-CD20 antibody is a highly effective regimen for iNHL. Though initially favoured for its toxicity profile, subsequent analyses demonstrate profound and prolonged lymphopenia and the landmark phase III GALLIUM study showed a grade 3-5 infection rate of 20-26% in the bendamustine arms (Hiddemann JCO 2018). The relationship between severity and duration of lymphopenia and infection, and the role of antimicrobial prophylaxis (ppx), are not fully characterised. We performed a multicentre, retrospective analysis of bendamustine-treated iNHL patients (pts) to define the type and onset of infections, identify concomitant risk factors and evaluate the r..

View full abstract